Tagged with M

Saudi Arabia Mohamed Al Holibi, Regional Business Lead for Health Information Systems at Solventum, shares insights into the evolving role of healthcare data and digital transformation in Saudi Arabia. In this interview, he discusses Solventum’s commitment to supporting Vision 2030 through advanced AI-driven technologies, the implementation of Diagnosis-Related Groups (DRG) systems, and…

Global Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and headwinds still persist, particularly around regulatory changes, affordability issues, and capital financing in the public and private markets, the healthcare…

Mexico This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth. By balancing structure with inclusivity, Ortiz implements best practices drawn from global experience while respecting GLR’s legacy as a family-owned…

Global In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain their CEOs, focusing instead on reshaping management at other levels. Companies like Bayer underwent sweeping transformations, while others, such as…

France François Bayrou’s new administration in France, sworn in after the previous, three-month-old government was toppled by a no-confidence vote, brings a new health minister to a post recently characterized by instability. With budget concerns looming and the doubtful staying power of the new cabinet, it remains to be seen how…

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Mexico Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical role in Lilly’s global strategy. Alcazar offers insights into the company’s focus on innovation, diversity, and patient-centricity, as well as…

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

USA While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the finish line. Oncology remained the single largest focus area among last year’s endorsed therapies and as opposed to 2023 when…

Mexico Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture, especially among younger generations, and the role of innovation in Mexico’s evolving healthcare landscape.   Investing in children’s health education…

Puerto Rico Gustavo A. Hermida, President of CIC Construction Group, shares the remarkable journey of Puerto Rico’s leading general contractor. Built on a foundation of excellence in the pharmaceutical sector, CIC has successfully diversified into healthcare, hospitality, and housing while upholding its rigorous standards of safety, quality, and timely delivery. Hermida highlights…

Germany A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’ withdrawal from purchase of Evotec; Merck KGaA-controlled MilliporeSigma’s acquisition of HUB Organoids, and Gilead’s USD 465 million solid tumour deal…